secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066971
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics Q1 net loss $10.3M; positive RIVER trial results; CORAL data expected Q2 2025
--------------------------------------------------------------------------------

- Net loss of $10.3M ($10.9M YoY); R&D expenses $7.8M, G&A $3.7M.
- RIVER Phase 2a positive: 67% cough reduction from baseline, 57% placebo-adjusted (p<0.0001).
- CORAL Phase 2b enrollment completed Feb 2025; last patient visit Apr 2025; topline results on track for Q2 2025.
- Cash, equivalents and marketable securities $103.3M; runway expected into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025066971/0000950170-25-066971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025066971/trvi-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer